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Objective: Keloid disease (KD) is a benign ﬁbroproliferative skin tumor that results
from abnormal wound healing and has no single deﬁnitive treatment. This study aims
to identify KD biomarkers, which are cellular mediators that can serve as indicators
of normal, pathological, and therapeutic processes. Methods: Bioinformatics analytic
approaches, including comprehensive literature searches and DAVID Bioinformatics
Resources 2008, were performed on the established KD linkage and previously reported
microarray data to identify potential candidate genes for the study. Keloid margins and
unaffected skin were obtained from KD patients (n = 4). RNA was extracted from
the biopsies and second-passage culture equivalents. Reverse-transcriptase quantitative
polymerase chain reactions were used to determine the gene expression levels. Student
t tests were used to analyze the statistical signiﬁcance in differential gene expressions.
Results: Nineteen candidate genes were initially selected by bioinformatics analysis.
Of the 19 genes, 10 were signiﬁcantly (P < .05) upregulated in keloid margin biopsy
specimens. The top-5 fold changes range from 10-fold to 175-fold, including aggrecan;
asporin; inhibin, beta A; tumor necrosis factor-α inducible protein 6; and chromosome 5
openreadingframe13.Therewasnosigniﬁcantdifferentialgeneexpressionbetweenthe
ﬁbroblasts established using keloid margin or internal control sites. Conclusions: The
transcriptomic data generated from cultures did not consistently correlate to the biopsy
equivalents. This study has demonstrated 10 genes that are signiﬁcantly upregulated in
biopsy samples of keloid margin, 5 of which have a fold change higher than 10-fold.
Importantly these genes may serve as a potential biomarker for KD.
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Keloid disease (KD) is a benign dermal ﬁbroproliferative tumor unique to humans
which is thought to occur following an abnormal wound healing process.1 Keloid scars are
aesthetically disﬁguring often impair function as they can restrict skin and joint mobility,
and have the potential to cause intense symptomatic (itch and pain) distress.2 There is
currently no satisfactory treatment of KD because high recurrence rates and undesirable
side effects have been observed irrespective of the intervention.3
Hence,theestablishmentofmoreeffectivetherapeuticstrategies,betterunderstanding
andcharacterizationofthemolecularmechanismsinvolvedinKDareconsideredimportant
developments. Biomarkers are biological mediators that may be used as an indicator of
normal biological processes, pathogenic mechanisms or pharmacologic responses to a
therapeutic intervention.4 By identifying new KD biomarkers, the disease process and
treatment approach may be better characterized.
IncontrasttoKD,hypertrophicscars,anotherformofexcessiveraiseddermalscarring,
rarely reoccur after excision.5 Unlike hypertrophic scars, KD characteristically extends
beyond the original wound boundary6. The margin of KD spreads into the surrounding
healthy skin through invasion, rather than expansion, with a leading edge that is often
erythematous and pruitic.6,7 The unusual invasive properties of the KD margin make it an
interesting target to study and compare with normal skin.
When keloid-derived ﬁbroblasts, the major cell type in KD, are compared with ﬁbrob-
lasts derived from normal skin or hypertrophic scars, the keloid-derived ﬁbroblasts show
several abnormal changes including excessive extracellular matrix production and prolifer-
ation,alteredapoptosis,growthfactorresponseandcytokineproduction.3 Althoughtheuse
of tissue cultures would allow studying the gene expressions of a single cell type, such as
a ﬁbroblast, researchers often neglected the changes in cellular environment culturing con-
ditions introduce. There are currently a limited number of studies that have examined gene
expression levels in biopsy and cell culture samples simultaneously.8-11 In this study, we
compared gene expression levels in tissue biopsy and cell culture, which were both derived
from the same biological sample obtained from the same individual and then compared
with similar samples harvested from different individuals.
This study, using bioinformatics analysis, aims to select the most freqently reported
genes from previous literature of keloid susceptibility loci and existing microarray data by
the frequency they have been reported. The gene expression levels in the margins of KD
specimens are compared with those of unaffected skin from the same patient. Additionally
gene expression levels in tissue biopsies will also be compared with those of tissue cultures
to determine whether similar results are observed.
MATERIAL AND METHODS
Patients and samples
Samples from 4 patients were used in this study. The mean age was 29 ± 4 years.
Three patients were white, and the fourth patient was of white/black Caribbean ancestry
(Table 1). Biopsies of normal skin and keloids margin were obtained (Fig 1).
Tissue culture
Primary tissue cultures were obtained by enzymatic digestion of biopsies. The collected
samples were minced into small pieces with sterile scalpels and incubated in 0.25% to
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5% collagenase A solution (Roche Diagnostics GmbH, Mannheim, Germany) at 37◦Cf o r
2.5 to 3 hours. The collagenase digestion was inhibited using ﬁbroblast culturing media.
The ﬁbroblast culturing media consists of Dulbecco’s modiﬁed Eagle’s medium 3 (Lonza,
Verviers, Belgium), supplemented with 10% heat-inactivated fetal bovine serum (Sigma,
Gillingham, UK), 1% penicillin/streptomycin (Lonza), and 1% non–essential amino acids
(Lonza).
Table 1. Patient details
Study ID Age, y Gender Race/ethnicity Site
KS41 34 Female White Shoulder
KS42 24 Female White/black Caribbean Sternum
KS43 30 Female White Shoulder
KS44 26 Female White Sternum
Figure 1. Illustration of the lesional sites of keloids taken in this study.
After the digestion, each sample was spun at 1,200 rpm for 5 minutes, re-suspended in
ﬁbroblast culturing media, and seeded in 25-cm2 culturing ﬂask (Corning, Corning, NY).
The cultures were maintained at 37◦C and 5% CO2, and the media was replaced every 48
hours. Passaging was carried out with trypsin-ethylene diamine tetraacetic acid (200 mg/L
of ethylene diamine tetraacetic acid, 500 mg/L of trypsin; Lonza) when approximately 80%
conﬂuence was reached.
RNA extraction
Four pieces of 2-mm3 tissue were cut off from each biopsy sample that had been stored in
RNAlater.Eachpieceof2-mm3 tissuewasﬁnelydicedandplacedin2-mLround-bottomed
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Eppendorf tubes with a ﬂame-sterilized steel ball bearing and 1 mL of Trizol (Invitrogen,
Carlsbad, Calif). The tissues in the Epppendorf tubes were homogenized by Qiagen tissue
lyser (Qiagen, Hilden, Germany) that was set at 30 beats per second for 12 minutes. The
homogenized tissue suspension was transferred to a sterile 1.5-mL Eppendorf tube and
centrifuged at 13,000 rpm for 10 minutes to remove cell debris. After the centrifugation,
the resulting supernatant were transferred to a new Eppendorf tube and mixed with 0.2 mL
of chloroform/1 mL of Trizol (Invitrogen). Solutions in each tube were mixed well and left
at room temperature for 2 minutes, after which the mixtures were centrifuged at 13,000
rpm for 15 minutes. The upper aqueous layer in each tube was transferred into a fresh
Eppendorf tube and equal volume of 70% ethanol was added and mixed well.
The extracted RNA was further processed using RNeasy kit (Qiagen, UK) according
themanufacturer’sinstructions,followedbyDNasetreatmentwithaDNAFreekit(Ambion,
Austin, Tex) according to the manufacturer’s protocol.
Complementary DNA synthesis
SuperScript II reverse transcriptase kit (Invitrogen) was used for synthesis of complemen-
tary DNA (cDNA). For each sample, 1000 ng of RNA, 1 μL of nucleotides mix (10 mM for
each nucleotide) (Invitrogen), 375 ng of oligo-dT, 62.5 ng of random primers, and sterile
nuclease-free water (Ambion) were mixed in a nuclease-free Eppendorf tube to make up a
total volume of 12 μL. After incubation at 65◦C for 5 minutes and rapid cooling on ice, 2
μL of 0.1 M of DTT (Invitrogen), 1 μL of RNaseOut (Invitrogen), and 4 μL of ﬁrst-strand
buffer (250 mM of Tris-hydrochloride, pH 8.3 at room temperature; 375 mM of potassium
chloride; 15 mM of magnesium chloride; Invitrogen) were added to each tube. After incu-
bation at 25◦C for 2 minutes, 1 μL of SuperScript II reverse transcriptase (Invitrogen) was
added and incubated at 25◦C for a further 10 minutes, before being transferred to 42◦C
incubationfor 50 minutes.Followingthis,thesamplesareincubatedat70◦C for 10 minutes
to inactivate the enzymes.
Selection for candidate genes
Bioinformatics methods were used to select candidate genes. Through literature searches,
7 non–pathway-speciﬁc microarray gene proﬁling studies were identiﬁed, including stud-
ies of Smith et al,12 Seifert et al,7 Hu et al,13 Naitoh et al,14 Satish et al,15 and Chen
et al,16,17 and a list of genes from own unpublished data (Table 2). Full list of upregulated
or downregulated genes were collected, and all given gene details were converted into the
National Center for Biotechnology Information (NCBI) ofﬁcial gene symbol by DAVID
Bioinformatics Resource 2008. Entries unrecognized by DAVID Bioinformatics Resource
2008 were converted manually by searching the NCBI database. Whether the reported
dysregulation was upregulation or downregulation was also noted for each gene. Candidate
genes were selected by the following criteria: (1) reported in 3 or more microarray studies;
(2) reported in 2 or more microarray studies with agreeing upregulation or downregulation
that were not further conﬁrmed; (3) all genes that have more than 10 results from Scopus
search term “keloid” and “gene name” were excluded from the study; (4) include the genes
that have been reported in any microarray and; (5) a list of genes from our own unpublished
data (Table 3).
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Table 3. Genes selected from microarray studies
Ofﬁcial Number of Studies Reported upregulation/ Biopsy or
gene symbol microarray reports mentioned downregulation culture
A2M 2 Hu et al (2006) Up Biopsy
Chen et al (2003) Up Biopsy
ACAN 2 Seifert et al (2008) Up Culture
Naitoh et al (2005) Up Culture
ANXA1 2 Hu et al (2006) Up Biopsy
Seifert et al (2008) Up Culture
ASPN 1 Smith et al (2008) Up Culture
C5ORF13 3 Naitoh et al (2005) Up Culture
Hu et al (2006) Up Biopsy
Smith et al (2008) Up Culture
EGFR 2 Hu et al (2006) Down Biopsy
Seifert et al (2008) Down Culture
HDGF 2 Hu et al (2006) Down Biopsy
Chen et al (2003) Down Biopsy
HIF1A 2 Hu et al (2006) Up Biopsy
Seifert et al (2008) Up Culture
IGFBP5 3 Hu et al (2006) Down Biopsy
Seifert et al (2008) Up Culture
Smith et al (2008) Up Culture
IGFBP7 2 Hu et al (2006) Up Biopsy
Seifert et al (2008) Up Culture
Smith et al (2008) Down Culture
INHBA 1 Seifert et al (2008) Up Culture
LGALS1 1 Hu et al (2006) Up Biopsy
PTN 3 Chen et al (2003) Up Biopsy
Hu et al (2006) Up Biopsy
Smith et al (2008) Down Culture
SERPINF1 2 Hu et al (2006) Down Biopsy
Na et al (2004) Down Biopsy
SERPINH1 2 Hu et al (2006) Up Biopsy
Smith et al (2008) Up Culture
A2M indicates alpha-2-macroglobulin; ACAN, aggrecan; ANXA1, annexin A-1; ASPN, aspirin; C5ORF13,
chromosome 5 open reading frame 13; EGFR, epidermal growth factor receptor; HDGF, hepatoma-derived
growthfactor;HIF1A,hypoxiainduciblefactor1,alphasubunit;IGFBP,insulin-likegrowthfactorbindingpro-
tein; INHBA, inhibin, beta; LGALS1, lectin, galactoside-binding, soluble, 1; PTN, pleiotrophin; SERPINF1,
serpin peptidase inhibitor, clade F; and SERPINH1, serpin peptidase inhibitor, clade H.
In addition, candidate genes were also selected from linkage regions reported by
Marneros et al.20 Genes located between the markers D2S1328 and D2S2275 on chromo-
some 2 and between the markers D7S1818 and D7S4737 on chromosome 7 were identiﬁed
using Ensembl (http://www.ensembl.org/index.html).
Thorough English language literature searches were carried out and genes
likely to be involved in KD were selected. The selected genes were clustered
through the tool, functional annotation clustering, provided in DAVID Bioinformatics
Resources 2008 (http://david.abcc.ncifcrf.gov:8080/home.jsp). Annotation categories used
for the functional clustering included all functional categories (COG ONTOLOGY,
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PIR SEQ FEATURE, SP COMMENT TYPE, SP PIR KEYWORDS, and UP SEQ
FEATURE), all pathways (BBID, BIOCARTA, EC NUMBER, KEGG PATHWAY,
and PANTHER PATHWAY), all diseases (GENETIC ASSOCIATION DB DISEASE,
OMIM DISEASE, and GENETIC ASSOCIATION DB DISEASE CLASS), 3 protein
domains (INTERPRO, PIR SUPERFAMILY, and SMART), and 3 gene oncology
(GOTERM BP ALL, GOTERM CC ALL, and GOTERM MF ALL). The classiﬁcation
stringency was set to highest. Where possible, 1 candidate gene was selected from each
cluster as a representative of the functional group.
Selection for reference genes
The selection of suitable reference genes was carried out using GeNorm.21 Seven
reference genes were used to screen for the most stably expressed reference genes,
including β-actin (ACT-β), β-2-microglobulin (β2M), glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), hydroxymethyl-bilane synthase (HMBS), hypoxanthine
phosphoribosyl-transferase I (HPRT), ribosomal protein L32 (RPL32), and succinate de-
hydrogenase complex subunit A (SDHA).21,22 The most stable reference genes across all
biopsy, culture, normal, and margin samples were selected.
Reverse transcriptase-quantitative polymerase chain reaction
Reversetranscriptase-quantitativepolymerasechainreactions(RT-qPCRs)werecarriedout
using LightCycler 480 platform (Roche Diagnostics GmbH). Polymerase chain reactions
were performed in 384 multiwell plates (Roche Diagnostics GmbH). Three replicates of
each reaction were carried out. The reaction volume was composed of 4 μL of 1:20 diluted
template cDNA, 5 μL of LightCycler 480 Probes Master (Roche Diagnostics GmbH),
0.2 μM of each primer (Metabion International AG, Martinsried, Germany) (Table 4),
0.1 μL of probe from Universal Probe Library (Roche Diagnostics GmbH), and nuclease-
free water (Ambion) to make up to a total volume of 10 μL. Four microliters of nuclease-
free water was used to substitute for the template cDNA for the no template controls.
LightCycler 480 software, Version 1.2 (Roche Diagnostics, Burgess Hill, England) was
used to specify the qPCR conditions and to calculate the threshold cycle number (CT).
The qPCR conditions were programmed as follows: First, there was 1 cycle at 95◦Cf o r5
minutes for the activation of Hot Start Taq polymerase. Then, 45 ampliﬁcation cycles were
carried out; each cycle consisted of denaturation at 95◦C for 10 seconds and annealing and
extension at 60◦C for 30 seconds. Finally, a cooling cycle was programmed at 40◦C for 10
seconds. The reading of ﬂuorescence level of the qPCRs in each ampliﬁcation cycle was
taken at the end of the 60◦C step. The second derivative method was used for determining
the CT.
Gene expression–level analysis
The statistical signiﬁcance of the difference in gene expression levels between the normal
skin and margin was determined by the relative CT method.23,24 The  CT for each gene
was obtained by deducting the average CT for the reference transcripts from the CT for
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Table 4. Primer details
Ofﬁcial gene symbol Transcript ID Forward primer Reverse primer Probe sequence
A2M NM 000014.4 ctacgagacggatgagtttgc cttctgtggagctctgagaaca tgctggag
ACAN NM 001135.2 cagatggacaccccatgc cttctgtggagctctgagaaca catcacca
NM 013227.2
ANXA1 NM 000700.1 aatgcacagcgtcaacagat tgtttcatccaggggcttt tctccagg
ASPN NM 017680.3 gacaccatgaaggagtatgtgc aagaagggtttggcagagc ttcctggc
C5orf13 NM 004772.1 tgtcccaaaggaagtgaacc attcttggggagcggagtt tgggcagc
EGFR NM 201284.1 catgtcgatggacttccaga gggacagcttggatcacact tgggcagc
NM 005228.3
NM 201282.1
NM 201283.1
HDGF NM 004494.2 acgagaaaggagcgttgaag tccttgggacgtttaggaga tgctggag
NM 001126050.1
NM 001126051.1
HIF1A NM 181054.1 cagctatttgcgtgtgagga cagctatttgcgtgtgagga ggatgctg
NM 001530.2
IGFBP5 NM 000599.3 aagcagggaacgcatgatt aagcagggaacgcatgatt ccaggctg
IGFBP7 NM 001553.1 ctgtcctcatctggaacaagg tgaatggccaggttgtcc ggcaggag
INHBA NM 002192.2 ctcggagatcatcacgtttg ccttggaaatctcgaagtgc gccaggaa
LGALS1 NM 002305.3 catcgtgtgcaacagcaag acacctctgcaacacttcca ggaggctg
PTN NM 002825.5 aactgaccaagcccaaacct ggtgacatcttttaatccagca caggagaa
SERPINF1 NM 002615.4 acgctatggcttggattcag atactcatgcttccggtcaag ttgcccag
SERPINH1 NM 001235.2 tgatgatgcaccggacag gatggggcatgaggatgat ggctggag
TNFAIP6 NM 007115.2 ggccatctcgcaacttaca cagcacagacatgaaatccaa agaggcag
MAP3K2 NM 006609.3 aaggctatggaagaaaagcaga tggctgagtggcgatttta attgctgc
LIMS2 NM 017980.2 ctgcgagactcactacaacca gacaccacatcgccttcaat gcagccat
BIN1 NM 139344.1 gtgatccccttccagaacc ttccagtcgctctccttcac tcctgctc
NM 139345.1
NM 139346.1
NM 139348.1
NM 139347.1
NM 139349.1
NM 139351.1
NM 139350.1
NM 139343.1
NM 004305.2
A2M indicates alpha-2-macroglobulin; ACAN, aggrecan; ANXA1, annexin A-1; ASPN, aspirin; BIN1, bridging integrator
1; C5ORF13, chromosome 5 open reading frame 13; EGFR, epidermal growth factor receptor; HDGF, hepatoma-derived
growth factor; HIF1A, hypoxiainducible factor 1, alpha subunit; IGFBP, insulin-like growth factor binding protein; IN-
HBA, inhibin, beta; LGALS1, lectin, galactoside-binding, soluble, 1; LIMS2, LIM and senescent cell antigen-like do-
mains 2; MAP3K2, mitogen-activated protein kinase kinase kinase 2; PTN, pleiotrophin; SERPINF1, serpin peptidase
inhibitor, clade F; SERPINH1, serpin peptidase inhibitor, clade H; and TNFAIP6, tumor necrosis factor, alpha-induced
protein 6.
the candidate transcripts (equation 1).24 Using a statistical method suggested by Yuan and
Stewart,24 the statistical signiﬁcance of the  CT of each gene in the normal and margin
samples was compared with each other by paired t test with the software SPSS, Version
14.0 (SPSS, Inc).
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a (1) Candidate gene CT – reference gene CT =  CT
Because2copiesofampliconshouldbeobtainedduringeachcycleofthePCR,2− CT
was used to represent the relative gene expression levels in natural numbers for presenting
the results in bar charts (equation 2).
(2) 2− CT = Relative gene expression for the candidate gene
The average fold change between normal and margin samples was then calculated
averaging the 2−  CT for all patients (equations 3 and 4).23
(3) Keloid margin  CT – normal skin  CT =   CT
(4) 2−  CT = Fold change of a candidate gene
A summary of steps taken to identify the potential biomarkers for KD is shown in
Figure 2.
RESULTS
Candidate gene selection
A total of 47 genes have been found to be present in 2 or more microarray studies. Fifteen
candidate genes, including alpha-2-macroglobulin (A2M), aggrecan (ACAN), annexin A-1
(ANXA1), asporin (ASPN), chromosome 5 open reading frame 13 (C5ORF13), epidermal
growth factor receptor (EGFR), hepatoma-derived growth factor (HDGF), hypoxia-
inducible factor 1, alpha subunit (HIF1A), insulin-like growth factor binding protein 5
(IGFBP5),insulin-likegrowthfactorbindingprotein7(IGFBP7),inhibin,betaA(INHBA),
lectin, galactoside-binding, soluble, 1 (LGALS1), pleiotrophin (PTN), serpin peptidase in-
hibitor, clade F (SERPINF1), and serpin peptidase inhibitor, clade H (SERPINH1), were
selected following the selection criteria.
One hundred and sixty-eight genes were identiﬁed to be present in the 2q23 keloid
linkage (between markers D2S410 and D2S1353) and 50 genes in the 7p11 keloid linkage
(between markers D7S1818 and D7S473). The list of candidate genes was shortlisted to
9 genes through a comprehensive literature search for genes that directly or indirectly
contribute to keloid etiopathogenesis. The criteria included relations to cell proliferation
andmigration,ﬁbrosis,inﬂammation,MAPkinasesignaling,tissuehomeostasisapoptosis,
tumor progression, and wound healing. The 9 genes included tumor necrosis factor-α
inducible protein 6 (TNFAIP6), activin receptor IIA (ACVR2A), mitogen-activated protein
kinasekinasekinase2(MAP3K2),myosinVIIB(MYO7B),LIMandsenescentcellantigen-
like domains 2 (LIMS2), dipeptidyl peptidase 10 (DPP10), bridging integrator 1 (BIN1),
epidermalgrowthfactorreceptor(EGFR),andvonWillebrandfactorCdomaincontaining2
(VWC2). Eight of the 9 input genes were clustered using DAVID Bioinformatics Resources
2008 into 9 groups according to their functional categories. Five genes were then selected
(Fig3),withatleast1genechosenfromeachcluster.Theselectedcandidategenesincluded
TNFAIP6, LIMS2, MAP3K2, BIN1,a n dEGFR.
Reference gene selection
RPL32 and SHDA were identiﬁed as most stably expressed reference genes across all
samples. The pairwise variation in the 2 genes was less than 0.15, the threshold below
which the inclusion of additional reference genes was not required. The 2 reference genes,
RPL32 and SHDA, were therefore used as the internal control genes for the normalization
in RT-qPCRs.
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Figure 2. Flowchart summarizing steps taken and ﬁndings in this study. cDNA indicates
complementary DNA; RPL32, ribosomal protein L32; RT-qPCR, reverse-transcription
quantitative polymerase chain reaction; and SDHA, succinate dehydrogenase complex
subunit A.
RNA quality
The values of RNA integrity number (RIN) for all samples were higher than 7.0; a RIN
value of more than 5.0 indicated good total RNA quality, whereas a RIN value of more than
8.0 indicated best total RNA quality.25
Gene expression levels of candidate genes
A statistically signiﬁcant (P < .05) differential expression and a fold change of more than 2
were determined between keloid margin and internal control biopsy samples for 10 genes,
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including ACAN, ASPN, C5orf13, HIF1A, IGFBP7, INHBA, LGALS1, PTN, SERPINH1,
andTNFAIP6 (Table5).ACAN,ASPN,INHBA,TNFAIP6,andC5orf13werethe5candidate
genes showing the highest average fold change in margin biopsies (fold change ≥ 9.9)
(Fig 4). However, the signiﬁcant high fold changes between normal and keloid margin
samples was not observed in culture samples (Fig 4).
Figure 3. Functional clustering of the genes present within the keloid susceptibility loci.
Selected genes present within keloid susceptibility loci, 7p11 and 2q23, have been function-
ally clustered using DAVID Bioinformatics Resources 2008 Functional Annotation Tool. The
genes are separated into 9 separated category, and at least 1 gene from each categories has
been selected for downstream quantitative polymerase chain reaction analysis. The selected
genes are marked with a box around them. EGFR indicates epidermal growth factor recep-
tor; BIN1, bridging integrator 1; LIMS2, LIM and senescent cell antigen-like domains 2;
MAP3K2, mitogen-activated protein kinase kinase kinase 2; TNFAIP6, tumor necrosis factor-
α inducible protein 6; ACVR2A, activin receptor IIA; DPP10, inactive dipeptidyl peptidase
10; and MYO7B, myosin VIIB.
DISCUSSION
Throughcomprehensiveliteraturesearchesandbioinformaticsanalyticapproaches,15can-
didate genes were identiﬁed from published microarray data sets and 4 from previously
determined keloid linkage loci. Ten of these 19 genes, including ACAN, ASPN, C5orf13,
HIF1A, IGFBP7, INHBA, LGALS1, PTN, SERPINH1,a n dTNFAIP6 (Table 5), demon-
strated a statistically signiﬁcant difference for the gene expression levels between keloid
margin and internal control skin.
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Table 5. Signiﬁcant upregulation/downregulation
Probability Average fold change
Ofﬁcial gene
symbol Gene name Biopsy Culture Biopsy Culture
A2M alpha-2-macroglobulin 0.109 0.292 2.4 2.7
ACAN aggrecan 0.046 0.676 174.7 20.5
ANXA1 annexin A-1 0.061 0.120 1.2 0.9
ASPN asporin 0.004 0.822 96.3 3.2
C5ORF13 chromosome 5 open reading frame 13 0.000 0.868 9.9 1.4
EGFR epidermal growth factor receptor 0.003 0.185 0.6 0.7
HDGF hepatoma-derived growth factor 0.004 0.827 0.7 1.1
HIF1A hypoxia-inducible factor 1, alpha subunit 0.006 0.265 2.1 0.8
IGFBP5 insulin-like growth factor binding protein 5 0.304 0.665 1.8 0.9
IGFBP7 insulin-like growth factor binding protein 7 0.022 0.226 2.8 1.5
INHBA inhibin, beta A 0.031 0.636 14.0 3.0
LGALS1 lectin, galactoside-binding, soluble, 1 0.002 0.238 5.1 1.2
PTN pleiotrophin 0.041 0.912 7.8 0.9
SERPINF1 serpin peptidase inhibitor, clade F 0.115 0.649 2.6 1.0
SERPINH1 serpin peptidase inhibitor, clade H 0.003 0.390 5.7 1.2
TNFAIP6 tumor necrosis factor-α inducible protein 6 0.002 0.559 11.4 1.0
MAP3K2 mitogen-activated protein kinase kinase kinase 2 0.006 0.417 1.3 0.9
LIMS2 LIM and senescent cell antigen-like domains 2 0.580 0.582 0.9 1.5
BIN1 bridging integrator 1 0.248 0.919 1.6 1.1
The highest fold change between internal keloid normal and keloid margin was ob-
served in ACAN, with a fold change of approximately 175 (P = .046). The presence
and function of ACAN have been well characterized in cartilage but not in skin.26 ACAN
interacts with hyaluronic acid, which has been demonstrated to be present at higher levels
in keloid ﬁbroblasts.27
ASPN also showed a high level of signiﬁcant fold change (approximately 96-fold
upregulation) in keloid margins. Similar to ACAN, it is also a protein found in cartilage.
ASPN polymorphism and abundance have been associated with osteoarthritis, a disease
characterized by progressive cartilage degeneration.28 A 96-fold upregulation of ASPN has
been observed in keloid margin (P = .004). ASPN has been shown to directly bind to
transforming growth factor (TGF)-β1 in vitro and is suggested to be a negative regulator
for TGF-β in cartilage.28,29
Similarly, C5ORF13, also known as P311, has also been implicated to be a nega-
tive regulator for TGF-β1.30 The expression of C5ORF13 is shown to be upregulated by
approximately 10-fold in keloid margin (P = .000). The expression of C5ORF13 has
been shown to induce nonﬁbrogenic myoﬁbroblast-like phenotype in 3T3 cells, including
upregulation of smooth muscle α-actin, basic ﬁbroblast growth factor, vascular endothe-
lial growth factor, platelet-derived growth factor (PDGF), PDGF receptors and integrins
α3 and α5.30 However, unlike what is normally found in typical myoﬁbroblasts, P311-
induced myoﬁbroblasts downregulate TGF-β1 and its receptor TGF-βR2.30 The authors
have also suggested that C5ORF13 reduces the expression of matrix metalloproteinase
(MMP)-2 and MMP-9 mRNA.30 It has been postulated that the expression of C5ORF13 is
found in human wound myoﬁbroblast precursors and myoﬁbroblasts; C5ORF13-induced
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myoﬁbroblasts are thought to migrate in an ameboid pattern on ﬁbrin structures found in
the initial wound matrix, and the ameboid pattern is reversed to mesenchymal pattern upon
stimulation with TGF-β1.31 Furthermore reduced degradation of ﬁbrin has been observed
in keloid.32 and it is possible this ameboid migration pattern contributes to the aggressive
characteristics of the keloid margin.
Figure 4. Relative gene expression levels in all samples for 5 genes that are highly upregulated in
keloid margin. Signiﬁcant upregulation have been observed in the following 5 genes in biopsies of
keloid margin. However, this is not observed in the ﬁbroblast culture equivalents. ACAN indicates
aggrecan; ASPN, asporin; INHBA, inhibin, beta A; TNFAIP6, tumor necrosis factor-α inducible
protein 6; and C5orf13, chromosome 5 open reading frame 13.
INHBA showed a signiﬁcant 14-fold upregulation in keloid margin samples (P =
.031). Previously INHBA has been suggested to be a possible target gene by Seifert et al7
in a microarray study performed on ﬁbroblasts derived from keloids and external control
skin.TheauthorsobservedanincreasedmRNAexpressionofINHBAinﬁbroblastsderived
from all lesional sites of keloids when compared with external control skin. However, a
downregulation of INHBA protein level was observed when comparing keloid margin with
external normal skin.7 In addition, Seifert et al7 also noted an increased expression of
inhibitor for INHBA at the margin. The signiﬁcant difference in gene expression levels that
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Seifert et al observed between keloid and normal ﬁbroblasts was observed only in RNA
samples extracted from biopsies, not the ﬁbroblast cultures, in this study. This difference
may have been a result of the culturing conditions, which will be discussed in detail.
Smith et al12 determined signiﬁcant downregulation of PTN in keloid ﬁbroblast cul-
tures by microarray analysis. However, in our study, an approximate 8-fold signiﬁcant
upregulation (P = .041) was observed in keloid biopsies for PTN, which correlates to PTN
upregulation reported in keloid biopsies by Chen et al17 a n dH ue ta l 13 by microarray anal-
ysis. The discrepancy between the observations may be due to the different RNA sources
(e.g., from ﬁbroblast cultures or biopsy tissues).
The overexpression of SERPINH1, which showed a 5.7-fold upregulation in keloid
margin in this study (P = .003), has been suggested to promote excessive collagen depo-
sition in keloids.33 LGALS1 is a type of lectin that has been implicated in cell-cell and
cell-matrixinteractionsandhasbeensuggestedtobeinvolvedintumorprogression,atleast
partly, through the induction of T-cell apoptosis.34 IGFBP7 shows a 2.8-fold upregulation
in keloid margins (P = .022). Several other insulin-like growth factor–binding proteins
havebeendemonstratedtobedifferentiallyexpressedinkeloids.35 HIF-1α showsa2.1-fold
upregulation in keloid margins investigated in this study (P = .006). The expression of
aberrent HIF-1α and plasminogen activator inhibitor-1 (PAI-1), a downstream molecule
affected by HIF-1, in keloids has been well documented.36 In addition, treatment against
HIF-1α leads to downregulation of PAI-1.37
A statistically signiﬁcant (P = .002) ﬁnding was observed for the higher level of TN-
FAIP6transcriptsinkeloidmargins.TNFAIP6wasshowntobeinvolvedintheinhibitionof
neutrophil migration, modulation of inﬂammation, and tissue remodeling.38 In individuals
with renal ﬁbrosis, increased expression of TNFAIP6 was reported in the proximal tubular
epithelial cells, a cell population that was demonstrated to have the potential to contribute
to the pathogenesis of renal ﬁbrosis.39 Similar to ACAN, TNFAIP6 also interacts with
hyaluronic acid, which has been shown to be upregulated in keloid ﬁbroblasts.27 Although
Marneros et al20 did not identify mutations or disease-associated polymorphisms in the
TNFAIP6 gene when screening genomic DNA of the affected and unaffected family mem-
bers of the Japanese family used to establish the 2q23 keloid linkage.There may however
be other undetected chromosomal abnormalities, such as mutations within introns.
While 10 of the investigated genes demonstrated signiﬁcant differential gene expres-
sion between the biopsies of keloid margin and internal control, no signiﬁcant differences
in gene expression levels were observed for any genes between their ﬁbroblast culture
equivalents. This observation suggested that careful interpretation must be done for the
transcriptomic analysis obtained from tissue cultures. Similarly, Dangles et al40 demon-
strated that culturing conditions have a profound impact on gene expression of bladder
cancers. On the other hand, Bignotti et al41 suggested that the use of short-term culturing
(passage 0) could enhance the purity of the ovarian serous papillary carcinoma (OSPC)
tumor cell population and without altering the OSPC gene expression patterns. The incon-
sistencymaybeduetothefollowingreasons:differentgenesofinterestfordifferentdisease,
differentexperimentalmethods(suchasthetechniquesusedforthegeneexpressionstudies
and culturing conditions) and the use of different passages.
Inthisstudy,asigniﬁcantupregulationwasobservedfor10ofthe19studiedtranscripts
in the biopsy samples of keloid margin when compared with normal skin adjacent to keloid
lesions (P < .05). These identiﬁed genes, including ACAN, ASPN, C5ORF13, EGFR,
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HDGF, HIF1A, IGFBP7, INHBA, LGALS1, PTN, SERPINH1,a n dTNFAIP6, may serve as
potentially important biomarkers for KD.
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